CHINA RESOURCES JIANGZHONG

China Jiangzhong’s flat trade masks a subtle upside; despite a solid 14.9bn market cap and diversified product mix, investors await regulatory approvals and partnership deals to lift the stock above its 52‑week low.

China Jiangzhong’s stock stays flat, but a new TCM product approval signals growth prospects for the pharma group, boosting investor confidence in 2026.